Zimbabwe has declined a substantial US health deal valued at $367m (£272m) over five years over the United States' demand for sensitive biological samples.
This move was revealed after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson has since clarified that the US was demanding access to biological samples for research and profit but was not willing to share the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further negotiations to find a agreement suitable to both sides so the country's critical HIV programme can continue.
Wider Background
This development comes after a comparable case in Kenya, where a court halted a similar health funding agreement following concerns were raised about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to enhance transparency and responsibility.
As per statements, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our people if a new health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were upending structures already established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to continued discussions with our US partners on how future co-operation could be structured in a manner that honours the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it acknowledged the government's concerns, but recommended that talks must proceed considering much of the country's Aids initiatives relied on foreign aid.
"Where technical issues exist, including those relating to information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The halted deal highlights the ongoing challenges between accepting crucial foreign assistance and safeguarding a country's data in an ever more data-driven world.